NEGIRI protokol - DBCG

Hayakawa T, et al. Growth-promoting activity of tissue inhibitor of metalloproteinases-1
(TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett
1992;298:29-32.
En fase II-undersøgelse af irinotecan ugentligt til patienter med lokal avanceret eller metastatiskHER 2
negativ brystkræft og øget antal kopier af topoisomerase 1(TOP1) genet.
Protokol version 16. maj 2013, amendment nr. 2
Forsøget er godkendt af Lægemiddelstyrelsen Eudract nr.: 2012-002348-26 og
Den Videnskabsetiske Komite, nr.: H-1-2012-066
47
Holten-Andersen MN, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and
patients with advanced cancer. Br J Cancer 1999;80:495-503.
Li G, et al. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast
epithelial cells. Cancer Res 1999;59:6267-75.
Luparello C, et al. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour
of clonal breast cancer cells. Breast Cancer Res Treat 1999;54:235-44.
Nakopoulou L, et al. The favourable prognostic impact of tissue inhibitor of matrix
metalloproteinses-1 protein overexpression in breast cancer. APMIS 2003;111:1027-36.
Newell KJ, et al. Expression and localization of matrix-degrading metalloproteinases
during colorectal tumorigenesis. Mol Carcinog 1994;10:199-206.
Polette M, et al. Detection and localization of mRNAs encoding matrix metalloproteinases
and their tissue inhibitor in human breast pathology. Invasion Metastasis 1993;13:31-7.
Ree AH, et al. High levels of messenger RNAs for tissue inhibitors of metalloproteinases
(TIMP-1) and TIMP-2) in primary breast carcinomas are associated with development of
distant metastases. Clin Cancer Res 1997;3:1623-8.
Sieuwerts AM, et al. Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein
are differentially associated with prognosis in primary breast cancer. Clin Chem
2007;53:1280-8.
Yoshiji H, et al. Mammary carcinoma cells over-expressing tissue inhibitor of
metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J
Cancer 1998;75:81-7.
Yukawa N, et al. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in
patients with colorectal carcinoma. Br J Surg 2001;88:1596-601.
Zeng ZS, et al. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of
metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases.
Br J Cancer 1995;72:575-82.
Zeng ZS, et al. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer
stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995;1:899-
906.